Endovascular Embolization in Neurovascular Disease: Material Science, Multimodal Management, and Future Horizons

1. Introduction

Embolization is a minimally invasive endovascular procedure designed to block or restrict blood flow to specific anatomical regions, thereby mitigating the risks and physiological symptoms associated with neurovascular disease [1]. The historical trajectory of the field began in 1904, when Robert Dawbarn utilized paraffin and Vaseline to embolize head and neck lesions via the external carotid arteries [2]. However, it was the material science and interventional radiology advancements of the 1970s that triggered the exponential growth in the diversity and efficacy of embolic products available today [3].

Contemporary neurointerventional procedures are undergoing a fundamental shift: we are moving beyond the era of simple mechanical vessel blockage to embrace a new standard defined by bioactive integration and technological synergy. This evolution aims to transform embolic agents from passive fillers into active participants in the healing process. Vascular occlusion can be achieved through the deployment of mechanical devices, such as coils, plugs, and flow diverters, or via the injection of particulate and liquid embolic agents [4]. Selection of the appropriate modality is a complex decision-making process involving the analysis of vessel caliber, regional flow dynamics, the intended durability of the occlusion (temporary versus permanent), and the operator’s technical preference [5].

Mechanical devices offer advantages in high-flow environments due to precise placement and minimal risk of non-target embolization. Nevertheless, they are often limited by long procedure times, higher risks of recanalization, and technical difficulty when navigating complex or tortuous anatomy [6]. Complementary to these devices, injectable embolic agents are engineered to flow deep into the vasculature before solidifying. This capability makes them the primary choice for targeting smaller, more distal vessels that are inaccessible to larger mechanical devices [7]. Furthermore, these injectable agents can serve as specialized vehicles for the targeted delivery of drugs [8].

While embolization can serve as a definitive, standalone cure for select vascular lesions, its most frequent and critical role in contemporary neurointervention is as an essential adjunct within a multidisciplinary, multimodal treatment paradigm. Across diverse pathologies, ranging from complex congenital arteriovenous shunts to hypervascular neoplasms, the foundational goal of adjunctive embolization remains consistent: to strategically devascularize the target lesion [9]. In pathologies where surgical resection is necessary, embolization of high-flow arterial feeders and deep-seated microvascular networks prior to resection fundamentally alters local hemodynamics and facilitates surgical success [9,10]. This proactive modification minimizes intraoperative blood loss and improves surgical visualization, thereby enhancing the safety and efficacy of the definitive intervention [10,11].

This review provides a comprehensive synthesis of contemporary embolization strategies, focusing on non-device embolic agents and their clinical applications in complex neurovascular conditions, including arteriovenous malformations (AVMs), dural arteriovenous fistulas (dAVFs), hypervascular tumors, and chronic subdural hematomas (CSDH).

2. Embolic Agents: Advanced Material Characteristics

The selection of an embolic agent is governed by the lesion’s angioarchitecture, flow velocity, and the required depth of penetration.

2.1. Conventional Liquid Embolic Systems: Ethylene Vinyl Alcohol (EVOH) vs. Cyanoacrylates

Modern liquid agents are distinguished by their ability to achieve a permanent “cast” within the microvasculature, providing deep-seated occlusion. In the current clinical paradigm, these are categorized into two primary chemical classes: non-adhesive EVOH copolymers and adhesive cyanoacrylates.

2.1.1. Non-Adhesive EVOH Copolymers

EVOH is a synthetic, non-adhesive copolymer composed of ethylene and vinyl alcohol units. In neurointerventional applications, EVOH is dissolved in the biocompatible DMSO to create a liquid embolic agent. Current systems such as Onyx™ (Medtronic, Irvine, CA), Squid™ (Balt, Montmorency, France), and PHIL™ (MicroVention, Aliso Viejo, CA) function via a precipitation mechanism. When the solvent DMSO diffuses into the blood, the EVOH copolymer solidifies from the outside-in, forming a spongy mass. This unique phase transition allows for prolonged, “plug-and-push” injections, which are critical for filling complex bAVM nidi or dAVF shunts without immediate catheter entrapment [12,13]. However, DMSO is angiotoxic and can induce vasospasm or inflammatory responses [14].

2.1.2. Adhesive Cyanoacrylates

The primary agent in this class is n-butyl cyanoacrylate (n-BCA; e.g., TRUFILL^®). This adhesive “glue” undergoes a rapid, exothermic polymerization reaction upon contact with ionic substances (blood). The polymerization rate is highly dependent on the ratio of n-BCA to ethiodized oil, requiring precise timing to avoid unwanted adherence to the delivery catheter. Because it polymerizes nearly instantly upon contact with the target, adhesive cyanoacrylates are preferred for high-flow shunts where rapid, permanent stabilization is required [15,16].

2.2. Mechanical and Particulate Dynamics

Bioactive Coils: Modern coils, such as the Matrix™ (Stryker, Kalamazoo, MI) or HydroCoil^® (MicroVention, Aliso Viejo, CA), utilize poly(glycolide-co-lactide) (PGLA) and expandable hydrogels (copolymer of acrylamide and acrylic acid), respectively, to increase packing density and facilitate neointimal formation, addressing the high recanalization rates historically seen with bare platinum [17,18].

Traditional Polyvinyl Alcohol (PVA) Particles: Derived from a cross-linked polyvinyl alcohol sponge that is mechanically ground or rasped into shards, traditional PVA represents the foundational particulate embolic agent. Unlike the biologically inert casts formed by liquid agents, the primary mechanism of action for PVA relies on an intense, biologically active foreign body response. Upon deployment, the irregular, angular morphology of the particles promotes mechanical wedging within the vessel lumen. This physical occlusion is rapidly followed by aggressive localized vessel wall inflammation, angionecrosis, and the infiltration of multinucleated giant cells, ultimately culminating in permanent fibrosis and thrombosis [19,20]. Due to their irregular size and shape, these particles frequently aggregate, leading to more proximal occlusion than their specified size range might otherwise dictate [8].

Calibrated Microspheres: Unlike irregular polyvinyl alcohol (PVA) particles that may aggregate proximally, tris-acryl gelatin microspheres (e.g., Embosphere^® [Merit Medical, South Jordan, UT]) are highly calibrated for precise distal penetration, making them the standard for terminal arteriolar occlusion in hypervascular tumors [21,22].

3. Clinical Applications in Neurovascular Pathologies

3.1. Brain Arteriovenous Malformations (bAVMs)

Fundamentally, bAVMs are congenital vascular anomalies defined by a nidus: a tangled vascular network where feeding arteries shunt directly into draining veins without an intervening capillary bed [23]. This structural defect creates a high-flow, low-resistance environment driven by loss-of-function genetic mutations in the Bone Morphogenetic Protein (BMP) signaling pathway, particularly in genes like ENG or ACVRL1, which disrupt normal vascular endothelial growth [24]. Consequently, high arterial pressure is transmitted directly to thin-walled draining veins, often resulting in their rupture and subsequent intracranial hemorrhage. Furthermore, the aggressive shunting of blood through the nidus can reduce perfusion pressure in adjacent healthy brain tissue (a phenomenon known as vascular steal); this, alongside chronic venous hypertension and hemosiderin deposition, contributes to focal neurological deficits, seizures, and headaches [25,26].

Understanding these pathological features is critical for strategic management, as embolization is frequently employed to mitigate high-risk angioarchitectural features and reduce nidal volume prior to definitive intervention [9]. The management of bAVMs is dictated by the Spetzler-Martin (SM) Grade, which assesses surgical risk based on nidus size, eloquence of adjacent brain tissue, and the presence of deep venous drainage [27].

3.1.1. Hemodynamic Goals of Embolization

While standalone curative embolization is technically feasible for select small, low-grade (SM Grade I-II) lesions with favorable angioarchitecture, the established clinical benchmarks for small bAVMs (<3 cm) remain stereotactic radiosurgery (SRS) alone or microsurgery due to their high cure rates (>90%) with minimal surgical morbidity [28]. For medium-sized lesions (3–4 cm, typically representing Spetzler-Martin Grade III), the therapeutic strategy often requires a tailored, combined approach. Microsurgical resection remains the primary modality for achieving immediate, definitive cure in surgically accessible nidi, while SRS is frequently employed to complete the obliteration of complex remnants in eloquent regions. Ultimately, within a multidisciplinary framework, embolization, utilizing liquid agents such as n-BCA or Onyx, is predominantly and strategically deployed as a vital adjunct to these definitive therapies [29]. Specifically, it serves three targeted hemodynamic objectives:

Pre-surgical Devascularization: In accordance with the multimodal paradigm, embolization is utilized to occlude deep-seated, surgically inaccessible arterial pedicles, thereby diminishing the hemodynamic pressure within the vascular tangle prior to microsurgical resection [28].

Pre-radiosurgical Volume Reduction: For nidal volumes exceeding 4 cm, the probability of achieving a cure with single-fraction SRS alone diminishes significantly. Strategic embolization is employed here to compartmentalize the high-flow components, thereby optimizing the radiation’s therapeutic index while shielding the adjacent healthy brain tissue from necrosis. By obliterating high-flow compartments, the efficacy of the focused radiation dose is enhanced while minimizing the risk of radiation-induced necrosis in surrounding parenchyma [10,30].

Palliative Hemodynamic Modification: In inoperable, deep-seated lesions (e.g., brainstem or thalamus), targeted embolization of intranidal or flow-related aneurysms is performed to reduce the acute risk of rupture [28,31].

The strategic selection of these multimodal interventions, based on nidal characteristics and clinical presentation, is summarized in Table 1.

3.1.2. Procedural Illustration: bAVM Embolization and Post-Procedural Management

The critical role of liquid embolization as an adjunct to definitive surgical resection or radiosurgery is heavily reliant on the deep, progressive permeation of EVOH-based agents into the complex microvascular architecture of the bAVM. The standard endovascular approach involves diagnostic angiography to clearly identify the high-flow nidus, the dominant arterial feeders, and the rapid venous drainage pathways (Figure 1A). Following super selective microcatheterization into the primary feeding pedicle (Figure 1B), lower-viscosity agents such as Onyx-18 are frequently utilized [34]. To prevent proximal reflux during these prolonged injections, operators may employ the “pressure cooker technique,” deploying microcoils within the feeding pedicle to create a mechanical barrier, as detailed in the magnified inset, prior to Onyx casting. The unique “outside-in” precipitation mechanism of Onyx allows for prolonged, carefully controlled injections. This technique facilitates the targeted opacification of the nidus while minimizing the risk of immediate catheter entrapment.

While this technique is highly effective in achieving a dense embolic cast that reduces nidal turgor and intraoperative blood loss prior to definitive microsurgery, this sudden angiographic obliteration carries inherent, severe risks. As highlighted in recent comprehensive analyses of Onyx embolization, the procedure carries a documented risk of acute intra- and post-operative hemorrhagic complications [34]. Notably, high-pressure casting is a primary driver of these events, accounting for up to 76.5% of intraoperative hemorrhages. Furthermore, operators must navigate this delicate balance by meticulously preserving venous outflow during the initial stages of injection; early or premature occlusion of the primary draining vein drastically increases intranidal resistance and exponentially elevates the risk of intraoperative rupture.

Independent of the immediate technical success of the embolic cast, sudden angiographic obliteration triggers profound localized hemodynamic shifts. The acute redirection of high-pressure arterial flow frequently precipitates normal perfusion pressure breakthrough (NPPB), occlusive hyperemia, and clinically significant vasogenic edema. Consequently, the isolated technical success of endovascular occlusion is merely the initial phase of patient management. Rigorous neurocritical oversight is absolutely mandatory to safely bridge the patient through the acute recovery phase. This requires active hemodynamic monitoring and targeted medical therapy, specifically the implementation of controlled hypotension to maintain strict physiological parameters—such as a systolic pressure of 80–90 mmHg or a mean arterial pressure of approximately 50–65 mmHg—to aggressively mitigate the risk of catastrophic delayed hemorrhage. Ultimately, this underscores the absolute necessity of a comprehensive, multidisciplinary neurovascular treatment paradigm.

3.2. Dural Arteriovenous Fistulas (dAVFs)

Dural arteriovenous fistulas (dAVFs) represent an acquired pathology characterized by the shunting of arterial blood directly into dural veins or venous sinuses. Unlike congenital arteriovenous malformations, most dAVFs are thought to be triggered by physiological stressors such as trauma, prior surgery, venous stenosis, or dural sinus thrombosis. These events likely initiate a cycle of local venous hypertension and subsequent neoangiogenesis, leading to the recruitment of meningeal arterial branches that bypass the normal capillary bed [35]. In dAVFs, this process is often driven by Notch signaling upregulation, which governs arterial-venous differentiation in response to chronic venous hypertension [36,37].

The clinical severity of a dAVF is determined by its venous drainage pattern. Utilizing the Cognard and Borden systems, “aggressive” phenotypes (Cognard III/IV, Borden III) are defined by the presence of cortical venous reflux (CVR), where high-pressure arterial flow is diverted into cortical veins. This retrograde flow results in venous hypertension, which carries a significant annual hemorrhagic risk of 8.1% and a mortality rate of 10.4% [38]. Consequently, the therapeutic goal focuses on the permanent obliteration of the fistulous point to normalize venous hemodynamics and eliminate the risk of catastrophic rupture [35].

3.2.1. Procedural Strategy: TAE vs. TVE

Transarterial Embolization (TAE): Leveraging EVOH agents, TAE is often first-line. The goal is to navigate the microcatheter as close to the shunt as possible, allowing the embolic agent to cross the fistulous point and partially fill the proximal venous outlet. This “cast” ensures the shunt is truly obliterated and cannot be recruited by collateral arterial supply [39].

Transvenous Embolization (TVE): TVE is highly effective for cavernous sinus dAVFs or lesions involving non-functional, thrombosed sinuses. However, TVE is strictly contraindicated if the involved sinus maintains exclusive or irreplaceable normal venous drainage. Its occlusion could precipitate catastrophic venous infarction. To definitively mitigate this risk, intraoperative adjuncts such as balloon test occlusion or venous manometry can be utilized to confirm sinus functional status and evaluate collateral venous capacity before committing to the permanent deployment of liquid embolic agents [40].

3.2.2. Multimodal Salvage and Synergy

The management of complex dural arteriovenous fistulas (dAVFs) frequently requires the coordinated integration of endovascular, surgical, and radiosurgical modalities to ensure complete obliteration of the shunt.

Preoperative Adjunct: For anatomically challenging, high-flow tentorial or petrosal dAVFs, TAE is strategically deployed to reduce arterial inflow and venous congestion prior to definitive microsurgical disconnection [41].

Microsurgical Disconnection: Surgery remains the definitive rescue strategy for dAVFs located in anatomically challenging regions, such as the anterior cranial fossa or ethmoidal junction, where arterial access is often unsafe, prohibitive, or excessively tortuous [42].

Stereotactic Radiosurgery (SRS): SRS functions as a secondary “clean-up” mechanism targeted at small, residual shunts characterized by low-risk venous drainage. Due to its inherent 1–3 year latency period, SRS is generally excluded as a primary intervention for high-grade lesions with active cortical venous reflux (CVR), as these patients require immediate protection against hemorrhagic events [43].

The synergistic application of these techniques within a specialized neurovascular team represents the contemporary clinical benchmark, optimizing efficacy and providing durable outcomes for complex lesions. Ultimately, because venous drainage architecture and access feasibility vary drastically by cranial region, the strategic sequencing of these endovascular, surgical, and radiosurgical interventions is fundamentally dictated by the specific anatomical location of the fistula. A comprehensive breakdown of these tailored multimodal strategies across distinct high-risk dAVF locations is detailed in Table 2.

3.2.3. Clinical Illustration: Tentorial dAVF Embolization Using a Coil-Assisted Anti-Reflux Technique

The clinical utility of advanced endovascular techniques is powerfully exemplified in the management of complex, high-risk lesions such as tentorial dural arteriovenous fistulas (dAVFs). These lesions frequently present with aggressive clinical features, such as cerebellar hemorrhage, and often recruit a complex arterial supply from deep, tortuous meningeal networks, including the meningohypophyseal trunk (MHT) and the medial tentorial artery (MTA) of Bernasconi-Cassinari. Achieving comprehensive embolic penetration of the fistulous point while protecting adjacent, normal neurovasculature requires highly precise flow-control strategies.

As demonstrated in recent literature, a transarterial approach utilizing a dual-microcatheter, coil-assisted anti-reflux technique provides exceptional control when deploying Onyx in these challenging anatomies [44]. In a representative case of a patient presenting with a ruptured tentorial dAVF (Figure 2A), an embolization microcatheter was navigated super-selectively into the MTA, while a secondary microcatheter was placed proximally within an aneurysmal dilation of the MHT.

Crucially, prior to liquid embolization, a protective coil mass was deployed within the MHT via the secondary catheter. This established a robust mechanical barrier or “plug.” During the active injection phase (Figure 2B), this proximal coil mass successfully arrested any retrograde reflux of the Onyx liquid embolic. By eliminating the path of least resistance backward along the catheter shaft, the agent was forced antegrade, driving deeper to comprehensively permeate the dAVF nidus and the proximal draining vein. The final post-procedural digital subtraction angiogram (Figure 2C) confirms complete, durable angiographic obliteration of the fistula with no residual high-flow shunting.

This case demonstrates the definitive curative potential of transarterial liquid embolization using advanced mechanical adjuncts, particularly when navigating anatomies with a high risk of embolic reflux. However, the sheer anatomical diversity of dAVFs often dictates the tailored, combined-therapy approaches previously outlined in this review.

3.3. Hypervascular Intracranial Tumors

Many aggressive intracranial tumors, including primary meningiomas and systemic metastases, are defined by their ability to recruit a robust, neoplastic arterial supply. The resulting tumor-specific neovascular networks exhibit strikingly abnormal features, most notably high-flow arteriovenous shunting, disorganized endothelial architecture, and increased capillary permeability [45]. Given this fragile and extensive vascularity, preoperative embolization is frequently deployed to selectively prune the tumor’s arterial supply, thereby mitigating the profound surgical risks of obscured dissection planes and hemorrhage [11].

3.3.1. Tumor-Specific Angioarchitecture and Molecular Drivers

The specific angioarchitecture and molecular drivers of this vascular proliferation vary significantly across different intracranial tumor subtypes.

Meningiomas and Complex Skull Base Tumors: Meningiomas are dural-based tumors that typically recruit their vascular supply from the middle meningeal artery (MMA) and other branches of the external carotid artery (ECA). Similarly, juvenile nasopharyngeal angiofibromas (JNAs) and paragangliomas often exhibit extensive recruitment of the internal maxillary artery alongside other complex ECA networks [46].

Renal Cell Carcinoma (RCC) Metastases: In contrast, systemic metastases like renal cell carcinoma (RCC) and melanoma exhibit aggressive arterial recruitment. In RCC, this angiogenic drive is frequently initiated by Von Hippel-Lindau (VHL) gene inactivation, which constitutively stabilizes hypoxia-inducible factors and massively upregulates Vascular Endothelial Growth Factor (VEGF) [47]. Consequently, RCC often recruits both meningeal and pial feeding vessels, necessitating aggressive devascularization strategies utilizing permanent agents like EVOH or PVA.

Melanoma Metastases: Parallel to this, metastatic melanoma frequently harbors BRAF gene mutations that elevate the risk of aggressive brain involvement. Its vascularity is highly heterogeneous; some lesions are not highly arterial, making the clinical benefit of embolization case-dependent [48].

The specific clinical roles of various embolic agents, alongside the comparative advantages of devascularization strategies for these neoplasms, are summarized in Table 3.

3.3.2. The Anatomy of “Dangerous Anastomoses”

The foremost procedural risk in tumor embolization is the existence of extracranial-to-intracranial (ECA-to-ICA/VA) anastomoses.

Non-Target Ischemia: Inadvertent migration of embolic material through these channels can precipitate ischemic stroke or cranial nerve palsies [52].

Common High-Risk Sites: Crucial anastomotic sites include the ophthalmic artery (via the ethmoidal branches), the inferolateral trunk (ILT), and the neuromeningeal branches of the ascending pharyngeal artery supplying the lower cranial nerves [53].

Mitigation Strategy: Successful devascularization requires superselective catheterization and a detailed understanding of skull base vascular variants to ensure the embolic cast remains isolated within the tumor bed [54,55].

3.3.3. Clinical Illustration: Standalone Embolization of a Hypervascular Meningioma

While the clinical utility of endovascular therapy for intracranial neoplasms is traditionally viewed as an adjunct to microsurgery, advancements in liquid embolic agents and microcatheter technologies have enabled the exploration of standalone embolization for highly selected hypervascular tumors. This minimally invasive paradigm is particularly relevant for small, asymptomatic meningiomas supplied exclusively by the external carotid artery (ECA) system, where aggressive surgical resection may carry disproportionate morbidity or patient preference dictates conservative management.

As demonstrated in recent multicenter evaluations, standalone embolization can achieve durable radiographic stabilization or active volume regression in these select cohorts [49]. In a representative case of a patient presenting with an incidentally discovered right sphenoidal ridge meningioma (Figure 3A), cerebral angiography confirmed a robust, singular arterial supply originating from the middle meningeal artery (MMA).

Utilizing a superselective technique, a microcatheter was navigated into the distal feeding pedicle (Figure 3B), followed by the controlled, progressive injection of the liquid embolic agent Onyx-18. The penetration of the liquid embolic allowed for a dense, total angiographic devascularization, obliterating approximately 90% of the tumor’s microvascular bed without the need for open craniotomy (Figure 3C). Long-term imaging in such cases frequently demonstrates subsequent tumor necrosis and volume reduction, underscoring the emerging potential of standalone liquid embolization as a definitive, minimally invasive alternative for highly selected meningiomas with favorable angioarchitecture.

3.4. Chronic Subdural Hematomas (CSDH)

The pathogenesis of a chronic subdural hematoma (CSDH) is defined by the gradual accumulation of blood and fluid within the space between the dura mater and the arachnoid membrane, typically occurring in the weeks following a mild head injury that causes the slow rupture of bridging veins. This pathology predominantly affects the elderly, individuals on anticoagulant therapy, and those with pre-existing brain atrophy [56,57]. The expansion of the hematoma is driven by a complex cycle of chronic inflammation and aberrant angiogenesis. As the initial blood collection lyses, it creates an osmotic gradient that draws in additional fluid. Concurrently, the surrounding hematoma membrane develops a network of fragile, hyperpermeable macrocapillaries supplied by the middle meningeal artery (MMA), which continuously leak plasma and blood into the subdural space [57,58]. This progressive expansion exerts a mass effect on the brain, leading to diverse neurological symptoms such as cognitive decline, persistent headaches, focal motor deficits, or seizures.

3.4.1. Rationale and Outcomes of MMA Embolization

Conventional surgical evacuation addresses immediate fluid collection but ignores the underlying vascular leakage; thus, CSDH management has increasingly shifted toward middle meningeal artery (MMA) devascularization [59]. Endovascular occlusion of these hyperpermeable neo-capillaries interrupts the chronic inflammatory exudation cycle, directly treating the hematoma’s pathophysiology [60]. While liquid embolic agents provide robust dural permeation, polyvinyl alcohol (PVA) particles have emerged as a highly favored and cost-effective alternative for MMA devascularization. Functioning as flow-directed agents, PVA particles are passively carried by the dominant hemodynamics directly into the capillary networks of the hematoma membrane. Furthermore, whereas liquid agents necessitate precise microcatheter positioning to manage rapid polymerization and solvent-related toxicity, PVA safely achieves deep, terminal arteriolar occlusion through distal mechanical wedging [61]. Strategic particle sizing (typically 150–350 μm) is paramount: particles must be small enough to penetrate the aberrant dural micro-network, yet large enough to prevent inadvertent shunting through high-risk extracranial-to-intracranial anastomoses [60]. Additionally, the use of PVA circumvents the need for specialized, DMSO-compatible microcatheters, reducing the logistical complexity of the intervention [62]. Clinically, MMA embolization addresses the underlying pathophysiology, reducing historical recurrence rates from 20% to 2–10% [63].

While particulate agents such as PVA have historically served as the cornerstone for reducing flow through meningeal networks, their lack of cohesive solidification limits their utility in achieving deep, permanent occlusion of fragile, high-pressure vascular beds. This limitation has driven a significant shift toward the utilization of liquid embolic agents. Unlike particulates, which act by physical obstruction, modern injectable agents are engineered to transition from a liquid to a solid state in situ, allowing for controlled, progressive penetration into the distal capillary networks. This transition—from simple mechanical flow restriction to comprehensive angioarchitectural obliteration—is best illustrated in the treatment of chronic subdural hematomas (CSDH), where liquid embolic agents are now being leveraged to neutralize the pathological neovascular membranes that drive hematoma recurrence.

3.4.2. Clinical Illustration: MMA Embolization for Chronic Subdural Hematoma

The management of chronic subdural hematomas (CSDH) has recently undergone a massive paradigm shift, driven by the understanding that pathological neovascular membranes are responsible for recurrent micro-hemorrhages and ongoing hematoma expansion. Middle meningeal artery (MMA) embolization has rapidly emerged as a transformative intervention designed to directly devascularize these fragile capillary networks, thereby promoting hematoma resorption and preventing recurrence.

The procedural execution of this technique relies on excellent distal penetration, as demonstrated in recent literature [64]. In a representative case of a patient presenting with a massive right-sided CSDH resulting in marked cortical compression and subfalcine herniation, standalone MMA embolization was pursued. Selective angiography of the right MMA (Figure 4A) clearly delineates the robust, pathological neovascular supply feeding the hematoma capsule. Utilizing a transradial approach, operators superselectively catheterized the distal MMA branches and deployed the liquid embolic agent n-BCA. Post-procedural angiography (Figure 4B) confirms the complete and durable obliteration of the abnormal meningeal supply, effectively neutralizing the source of recurrent bleeding.

Beyond technical feasibility, the clinical efficacy of this endovascular approach has now been rigorously validated by high-level, randomized controlled data. As demonstrated by the landmark STEM trial, the addition of MMA embolization to standard care dramatically alters the disease course [65]. Quantitative analysis (Figure 4C) confirms a highly significant reduction in overall treatment failure—evaluated as a composite metric of required surgical rescue or a lack of hematoma resolution—when compared to standard care alone (16% vs. 36%; P = 0.001). This robust validation solidifies targeted endovascular devascularization as a critical, front-line component in modern neurotrauma management.

3.5. Cerebral Aneurysms: The Constraint of Liquid Agents

The pathogenesis of cerebral aneurysms is a complex process driven by the interplay of aberrant hemodynamics, localized inflammation, and extracellular matrix remodeling, culminating in the structural degradation of the arterial wall. Originating predominantly at the apices of arterial bifurcations, elevated wall shear stress places chronic mechanical strain on the endothelium, disrupting its barrier function and upregulating cellular adhesion molecules that recruit circulating inflammatory cells [66]. Infiltrating macrophages and T-lymphocytes release pro-inflammatory cytokines and reactive oxygen species, creating a destructive microenvironment that hyperactivates matrix metalloproteinases. These enzymes systematically degrade structural proteins, fragmenting the internal elastic lamina and breaking down load-bearing collagen networks [67]. Concurrently, vascular smooth muscle cells within the arterial media undergo a phenotypic switch from a physiological contractile state to a pro-inflammatory synthetic state, eventually undergoing widespread apoptosis due to the ongoing stress [68].

Ultimately, this progressive loss of cells and structural matrix results in a highly degraded, thin-walled aneurysm sac. This fragile morphology makes the lesion exceptionally vulnerable to rupture, rendering it uniquely susceptible to the acute hemodynamic and thermal stresses introduced by liquid embolic agents during endovascular interventions [69,70]. Consequently, while liquid agents are essential for nidal lesions, they are rarely indicated as primary therapy for cerebral aneurysms due to two major safety constraints:

Hemodynamic and Thermal Stress: The polymerization of n-BCA is highly exothermic, and the DMSO solvent utilized in EVOH systems is angiotoxic; both properties can trigger acute rupture in these already thin-walled or dissecting aneurysms, inducing localized wall tension and potential thermal injury during the phase transition of the embolic agent [71,72].

Morphological Preservation: The primary goal in aneurysm treatment is complete sac occlusion with the strict preservation of the parent artery. The unpredictable “free-flow” nature of liquid embolic agents carries a prohibitive risk of reflux into the parent vessel, potentially necessitating emergent bypass surgery [73,74].

The inability to safely deploy current liquid agents within fragile, degraded aneurysmal sacs exposes the fundamental limitation of contemporary embolotherapy: it relies on inert, physically occlusive, and often biologically harsh materials. The acute thermal stress of polymerization and the unpredictable free-flow nature of these liquids underscore a critical clinical ceiling. To overcome these dual challenges of hemodynamic instability and procedural angiotoxicity, the field must evolve beyond simple mechanical blockage. This necessitates a paradigm shift toward dynamic materials that not only occlude but actively mitigate vascular stress and promote localized healing, setting the foundation for the next generation of precision neurointerventions.

4. Future Perspectives: Toward Precision Neurointervention

The field of neurovascular embolization is rapidly transitioning from a discipline defined by mechanical occlusion to one driven by molecular biology and advanced endovascular robotics. Future innovations aim to move beyond creating inert physical casts, leveraging bioactive scaffolds as dynamic platforms to actively guide cellular healing and utilizing robotics to achieve unprecedented procedural precision.

4.1. Molecularly Targeted Embolotherapy

The next generation of embolic materials will function simultaneously as occlusive agents and localized delivery vehicles for targeted molecular therapeutics.

Anti-Angiogenic Elution and Pathway Modulation: For aggressive dAVFs and hypervascular tumors, embolic matrices can be engineered to elute localized endothelial inhibitors, such as VEGF antagonists, directly into the nidus to halt post-procedural neoangiogenesis at the receptor level [75,76]. A primary biophysical challenge in these high-flow arteriovenous shunts is preventing the rapid hemodynamic washout of these therapeutics [77]. Overcoming this requires advanced polymer configurations, such as stimuli-responsive interpenetrating network hydrogels, that uncouple the physical macro-occlusion from the drug release kinetics [78]. By tethering molecular antagonists via enzymatically cleavable linkers or utilizing controlled-degradation microspheres, these scaffolds can maintain sustained, localized inhibition despite severe local shear stress [78,79]. Furthermore, therapies could be designed to modulate specific morphogenetic signaling cascades, such as the BMP pathway, which is critically implicated in hereditary hemorrhagic telangiectasia and aberrant vascular development [24,80,81]. Specifically, recognizing that AVMs often arise from loss-of-function mutations in the ACVRL1/ENG receptor complex, smart biomaterials could be engineered for the localized elution of recombinant BMP10 or targeted downstream inhibitors, such as Angiopoietin-2 antagonists [82,83]. By compensating for the deficient SMAD1/5/8 intracellular signaling cascade, these localized therapeutics could actively suppress the hyperproliferative, disorganized vascular phenotype characteristic of bAVM nidi, restoring endothelial quiescence and guiding true physiological remodeling [82,84].

Cellular Reprogramming and Endothelialization: Future bioactive scaffolds aim to address underlying cellular pathophysiology by inhibiting the pro-inflammatory, synthetic phenotypic switch of surrounding vascular smooth muscle cells (VSMCs) to instead promote organized, physiological endothelialization [85,86]. Achieving this targeted healing requires scaffolds functionalized with specific bioactive peptide sequences, such as RGD (Arg-Gly-Asp) or YIGSR (Tyr-Ile-Gly-Ser-Arg), designed to selectively engage endothelial cell surface receptors like the α_vβ₃ and α₅β₁ integrins [87,88]. This precise receptor-ligand interaction not only facilitates the recruitment and adhesion of circulating endothelial progenitor cells but also actively suppresses the hyperactivation of matrix metalloproteinases [89,90]. By stabilizing the extracellular matrix at the molecular level, these “smart” agents actively guide true vascular remodeling rather than functioning as inert mechanical plugs [88].

4.2. Endovascular Robotics and Computational Integration

However, the clinical realization of these highly sensitive, targeted molecular therapeutics is contingent upon their precise spatial delivery within complex vascular architectures. While smart biomaterials provide unprecedented biological precision, the field must simultaneously overcome the mechanical limitations of manual catheter navigation to fully exploit their potential. Consequently, the integration of robotic platforms with predictive computational models will fundamentally alter intraoperative capabilities, bridging the critical gap between molecular design and exact anatomical deployment.

Ultra-Distal Precision Navigation: Robotic-assisted systems provide sub-millimeter, tremor-free microcatheter manipulation, essential for navigating highly tortuous neo-networks and deploying liquid agents with steady-state injection pressures [91,92]. This mechanical stability will be uniquely critical when administering the next generation of stimuli-responsive hydrogels, ensuring exact local residence times before in situ crosslinking occurs.

Closed-Loop Hemodynamic Control: When integrated with Computational Fluid Dynamics (CFD), operators can calculate wall shear stress and local perfusion pressures before the embolic cast solidifies, executing staged occlusion strategies that actively prevent normal perfusion pressure breakthrough [93,94,95].

4.3. Smart Biomaterials and Active Clinical Trials

To fully leverage robotic precision, embolic agents are evolving into “smart” platforms evaluated through an expanding portfolio of clinical trials designed to validate next-generation platforms.

Stimuli-Responsive Systems: Research into thermoresponsive and ion-sensitive hydrogels includes the Embrace Hydrogel study, which is evaluating a PEG-based system designed for instantaneous in-situ crosslinking during the devascularization of hypervascular tumors [96,97,98]. These “aqueous ionic liquids” maintain a low-viscosity state during navigation but undergo predictable solidification to offer durable occlusion without the angiotoxicity of DMSO.

Material Advancements and Bioresorbable Scaffolds: The PHIL Evaluation and the Squid 12/18 Study are assessing low-viscosity EVOH copolymers to reduce imaging artifacts [13,99]. Concurrently, extracellular matrix (ECM)-derived hydrogels aim to create temporary occlusions that facilitate healing before fully resorbing [100,101].

Protocol Standardization and Automation: The MMA-CSDH Phase III multinational trial is rigorously validating how targeted devascularization impacts long-term recurrence compared to standard surgical evacuation [102,103].

The Future of Aneurysm Repair: While the Robotic-AVM Trial is primarily focused on achieving tremor-free delivery within fragile neo-networks, its validation of semi-autonomous platforms provides a critical technical foundation for the mechanical stability required to eventually expand liquid embolotherapy into complex aneurysmal sacs. This existing robotic framework, characterized by sub-millimeter precision, could theoretically transition aneurysm treatment from purely mechanical coiling toward a new paradigm of bioactive sac reconstruction. When paired with next-generation stimuli-responsive hydrogels that lack the exothermic and angiotoxic profiles of current agents, these robotic platforms offer a viable pathway to overcome the current “safety ceiling” of aneurysmal repair [74,104,105,106].

5. Conclusions

Endovascular embolization has evolved into an indispensable, cross-cutting modality within modern neurovascular practice. By seamlessly blending materials science innovation with precise angioarchitectural analysis, it provides a critical bridge in multimodal therapies. It significantly improves surgical safety profiles for complex brain arteriovenous malformations (bAVMs) and massive hypervascular tumors through robust preoperative devascularization, while successfully establishing a primary curative role in the management of aggressive dural arteriovenous fistulas (dAVFs) utilizing advanced flow-control techniques. Furthermore, recent rigorous randomized controlled data has cemented middle meningeal artery embolization as a transformative standalone therapy for chronic subdural hematomas (CSDH).

However, analyzing the profound physiological stressors, such as normal perfusion pressure breakthrough and vasogenic edema following high-flow shunt occlusion, underscores that technical angiographic success represents only the initial phase of patient management. Modern endovascular therapy necessitates rigorous, multidisciplinary neurocritical oversight to ensure true clinical success. Looking forward, the discipline is poised for a profound paradigm shift, transitioning from purely mechanical vessel occlusion toward precision, data-driven neurointervention (Figure 5). The integration of endovascular robotics and predictive computational fluid dynamics will empower operators to navigate ultra-distal anatomies and meticulously manage complex hemodynamics with unprecedented stability. Concurrently, the advent of molecularly targeted agents and stimuli-responsive “smart” hydrogels will transcend the creation of inert physical casts. By utilizing these materials as dynamic, bioactive delivery vehicles, the field will actively guide localized cellular healing and fundamentally redefine the future of integrated neurovascular outcomes.